Abstract

Cervical cancer can be prevented with the detection and treatment of precancerous lesions caused mainly by high-risk HPV genotypes, which cause more than 90% of cervical cancers [1,2]. The death rate from cervical cancer has declined in developed countries with organized screening programs [3] from 2.8 to 2.3 deaths per 100,000. Evidence is needed about the benefits and harms of HPV tests; in addition, the benefits and harms of various cervical cancer detection strategies; as the beginning of screening from the age of 21; Screening tests with cytology, HPV and Co-testing (cytology and HPV tests) and changes in age are variable from cytology to the HPV test, at age 25 , 27, 30 years, with the re-evaluation of the 3 to 5 years interval and the classification of the results for positive HPV-a (with genotypes VPH-16/18) or of the cytology. Screening strategies based on current guidelines include cytology alone every 3 years starting at age 21, and Co-testing every 5 years from 30 to 65 years.